Dr. Sheryl Marks is a board-certified Anesthesiologist and Medical Director with over 15 years of leadership experience in perioperative medicine and healthcare operations. She currently serves as Co-Medical Director and Principal Investigator at Rainier Clinical Research Center, where she leads early- and late-phase clinical trials focused on obesity, diabetes, hyperlipidemia, Alzheimer’s disease, vaccine development, and overall cardiometabolic health.
Prior to joining RCRC, Dr. Marks directed Swedish Medical Center’s Preadmission Clinic, where she oversaw the preoperative optimization of more than 35,000 surgical patients each year. In this role, she authored numerous clinical protocols and spearheaded system-wide initiatives in perioperative diabetes management, anemia optimization, and frailty risk assessment.
Dr. Marks brings a strong foundation in healthcare governance, having served as a founding Board Member of U.S. Anesthesia Partners–Washington and as Vice President of Medical Affairs at Physicians Anesthesia Service. Her experience spans strategic operations, interdisciplinary team leadership, and patient-centered innovation.
Since entering the clinical research field, Dr. Marks has served as Principal Investigator and Sub-Investigator on more than 40 clinical trials across Phases I–IV, collaborating with sponsors such as Novo Nordisk, Eli Lilly, Merck, Moderna, Abbott, Medtronic, Dexcom, and Tandem. Her therapeutic areas of focus include GLP-1 receptor agonists, mRNA vaccines, AID systems, monoclonal antibodies, lipid-lowering therapies, and CGM technology.
Dr. Marks earned her M.D. from Columbia University and completed her residency in Anesthesiology at the University of California, San Francisco. She lives in Seattle with her husband and three children.